retatrutide dosing clinical trial retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide Results After 40: Realistic
Description
The CEO of Novo Nordisk (NVO), the maker of Ozempic and Wegovy, said last year that food company executives were so scared they were calling him for advice on how to adapt to the new world of weight loss drugs
However, concerns around side effects, cost, and patient adherence remain significant
A friend or a coach can boost accountability
There is no universal answer, and personal comfort can change as your body, routine, or dose changes
Digestive issues are the most common complication
Wegovy is contraindicated in pregnancy and should not be used in patients with a personal or family history of medullary thyroid carcinoma
